How do biosimilars support the sustainability of the healthcare system? Cynthia Miller and Reta Mourad demonstrate how biosimilars reduce costs of biological therapies through increased competition, while also maintaining the quality of care.
Explore the top reasons payers are adopting clinical pathways and guidelines in the oncology space. Jennifer Williams shares the tumor types being targeted, as well as future possibilities payers are exploring in non-oncology specialties to further leverage pathways and guidelines.
Todd Edgar shares new perspectives on value-based contracting on how these contracts should be viewed, learnings from past years, and opportunities to make them a win-win for stakeholders.
Kellie Rademacher explores the complex world of biomarker testing including the several testing options available, the expansion of biomarkers, and the resulting challenges for various stakeholders.
Stay up-to-date as Ryan Cox discusses how accumulators and maximizers are being used by PBMs and health plans in response to continued pressure between plan benefit design, the expansion of manufacturer copay programs, and the growth of drug spending.